Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ramage

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Health Reports|January 30, 2013
Health behaviour changes after diagnosis of chronic illness among Canadians aged 50 or olderJason T Newson, Nathalie Huguet, Pamela L Ramage-Morin, et al.
Thorax|July 1, 1996
Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways diseaseA Grove, B J Lipworth, P Reid, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLVakul Mohanty, Natalia Baran, Yuefan Huang, et al.
Haematologica|April 20, 2023
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cellsYannan Jia, Lina Han, Cassandra L Ramage, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 14, 2008
Glucocorticoid receptor haploinsufficiency causes hypertension and attenuates hypothalamic-pituitary-adrenal axis and blood pressure adaptions to high-fat dietZ Michailidou, R N Carter, E Marshall, et al.
Blood|March 31, 2025
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AMLZhe Wang, Anna Skwarska, Gowri Poigaialwar, et al.
Research Square|May 10, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesisKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Biochemical Pharmacology|December 11, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitroKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Health Reports|January 30, 2013
Health behaviour changes after diagnosis of chronic illness among Canadians aged 50 or olderJason T Newson, Nathalie Huguet, Pamela L Ramage-Morin, et al.
Thorax|July 1, 1996
Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways diseaseA Grove, B J Lipworth, P Reid, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
Transcriptional and phenotypic heterogeneity underpinning venetoclax resistance in AMLVakul Mohanty, Natalia Baran, Yuefan Huang, et al.
Haematologica|April 20, 2023
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cellsYannan Jia, Lina Han, Cassandra L Ramage, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|August 14, 2008
Glucocorticoid receptor haploinsufficiency causes hypertension and attenuates hypothalamic-pituitary-adrenal axis and blood pressure adaptions to high-fat dietZ Michailidou, R N Carter, E Marshall, et al.
Blood|March 31, 2025
Efficacy of a Novel BCL-xL Degrader, DT2216, in Preclinical Models of JAK2-mutated Post-MPN AMLZhe Wang, Anna Skwarska, Gowri Poigaialwar, et al.
Research Square|May 10, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesisKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Biochemical Pharmacology|December 11, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitroKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Pageof 6